AZD2281
Showing 26 - 50 of 109
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 Trial in United
Recruiting
- Castration-Resistant Prostate Carcinoma
- +2 more
- Laboratory Biomarker Analysis
- +3 more
-
La Jolla, California
- +21 more
Dec 2, 2022
Recurrent DLBCL, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory DLBCL Trial in Houston (drug, procedure, other, biological)
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +4 more
- Busulfan
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 Trial in United States (Computed
Active, not recruiting
- Stage III Uterine Corpus Leiomyosarcoma AJCC v8
- Stage IV Uterine Corpus Leiomyosarcoma AJCC v8
- Computed Tomography
- +4 more
-
Phoenix, Arizona
- +14 more
Aug 23, 2022
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma Trial in
Active, not recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +24 more
- 18F-Fluoromisonidazole
- +4 more
-
La Jolla, California
- +15 more
Jan 3, 2023
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)
Active, not recruiting
- BRCA1 Gene Mutation
- +5 more
- Durvalumab
- +3 more
-
Buffalo, New York
- +1 more
Jan 20, 2023
Breast Tumors Trial in Worldwide (KU-0059436 (AZD2281) (PARP inhibitor))
Completed
- Breast Neoplasms
- KU-0059436 (AZD2281) (PARP inhibitor)
-
West Hollywood, California
- +16 more
Jan 24, 2023
Cancer Trial in United States (AZD2281, AZD5363, AZD1775)
Active, not recruiting
- Cancer
- AZD2281
- +3 more
-
New Haven, Connecticut
- +3 more
Sep 14, 2021
Laryngeal Cancer Stage II, Laryngeal Cancer Stage III, Carcinoma, Squamous Cell Trial in Amsterdam (radiotherapy, Olaparib)
Active, not recruiting
- Laryngeal Cancer Stage II
- +3 more
- radiotherapy
- Olaparib
-
Amsterdam, NetherlandsThe Netherlands Cancer Institute
Sep 27, 2022
Ovarian Tumors, BRCA1 Protein, BRCA2 Protein Trial in Worldwide (KU-0059436 (AZD2281)(PARP inhibitor))
Active, not recruiting
- Ovarian Neoplasms
- +2 more
- KU-0059436 (AZD2281)(PARP inhibitor)
-
Brussels, Belgium
- +4 more
Dec 19, 2022
Squamous Cell Carcinoma of Head and Neck Trial in Chapel Hill, Charleston (biological, drug, radiation)
Recruiting
- Squamous Cell Carcinoma of Head and Neck
- Pembrolizumab
- +3 more
-
Chapel Hill, North Carolina
- +1 more
Oct 25, 2022
Ovarian Cancer Trial in Manchester (Olaparib, Cediranib, Platinum-based Chemotherapy)
Completed
- Ovarian Cancer
- Olaparib
- +2 more
-
Manchester, United KingdomThe Christie NHS Foundation Trust
Feb 4, 2022
Prostate Cancer, Castration-resistant Prostate Cancer Trial in Washington, Baltimore (Olaparib, Vitamin C)
Not yet recruiting
- Prostate Cancer
- Castration-resistant Prostate Cancer
- Olaparib
- Vitamin C
-
Washington, District of Columbia
- +1 more
Aug 12, 2022
Recurrent Glioblastoma Trial in United States (Bevacizumab, Cediranib, Cediranib Maleate)
Active, not recruiting
- Recurrent Glioblastoma
- Bevacizumab
- +3 more
-
La Jolla, California
- +26 more
Jun 28, 2022
Ovarian Cancer Trial in Worldwide (AZD2281, matching )
Active, not recruiting
- Ovarian Cancer
- AZD2281
- matching placebo
-
Berkeley, California
- +73 more
Dec 19, 2022
Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma Trial in
Active, not recruiting
- Metastatic Esophageal Carcinoma
- +12 more
- Olaparib
- Ramucirumab
-
Corona, California
- +31 more
Aug 9, 2022
Advanced Malignant Solid Tumor, Glioblastoma, Recurrent Cholangiocarcinoma Trial in United States (Olaparib)
Recruiting
- Advanced Malignant Solid Neoplasm
- +6 more
-
Costa Mesa, California
- +49 more
Aug 24, 2022
Advanced Malignant Solid Tumor, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Recruiting
- Advanced Malignant Solid Neoplasm
- +28 more
- Capecitabine
- +16 more
-
Conroe, Texas
- +4 more
Dec 5, 2022
Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer Trial in Baltimore (Olaparib)
Recruiting
- Renal Cell Carcinoma
- +4 more
-
Baltimore, MarylandJohns Hopkins Sidney Kimmel Comprehensive Cancer Center
Mar 14, 2022
BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation, BRCA2 Gene Mutation Trial in Houston (Chemotherapy, Olaparib, Therapeutic
Recruiting
- BRCA-Mutated Ovarian Carcinoma
- +30 more
- Chemotherapy
- +2 more
-
Houston, TexasM D Anderson Cancer Center
May 27, 2022
Locally Advanced Malignant Tumor, Inflammatory Breast Carcinoma, Triple-Negative Invasive Breast Carcinoma Trial in Amsterdam
Completed
- Locally Advanced Malignant Neoplasm
- +2 more
- radiotherapy
- olaparib
-
Amsterdam, NetherlandsThe Netherlands Cancer Institute
Aug 3, 2021
Renal Cell Cancer Trial in Cambridge (Olaparib, Cediranib, Durvalumab)
Recruiting
- Renal Cell Cancer
- Olaparib
- +2 more
-
Cambridge, England, United KingdomAddenbrooke's Hospital
May 21, 2021
Locally Advanced Unresectable Breast Carcinoma, Metastatic Breast Carcinoma, Stage III Breast Cancer AJCC v7 Trial in United
Suspended
- Locally Advanced Unresectable Breast Carcinoma
- +3 more
- Atezolizumab
- +2 more
-
Phoenix, Arizona
- +57 more
Jul 27, 2022
Ewing Sarcoma, Rhabdomyosarcoma Trial in Boston, Memphis (Olaparib, Temozolomide, Irinotecan)
Recruiting
- Ewing Sarcoma
- Rhabdomyosarcoma
- Olaparib
- +2 more
-
Boston, Massachusetts
- +4 more
Oct 27, 2021